May 2017

ENDRA Life Sciences Inc. Completes IPO

ENDRA Life Sciences has commercialized an enhanced ultrasound technology for the pre-clinical research market and are leveraging that expertise to develop technology for increasing the capabilities of clinical diagnostic ultrasound, to broaden patient access to the safe diagnosis and treatment of a number of significant medical conditions in circumstances where expensive X-ray computed tomography, or CT, and magnetic resonance imaging, or MRI, technology is unavailable or impractical.  FaegreBD represented National Securities Corporation and Dougherty & Company as the underwriters in the offering.

Services & Industries

Faegre Baker Daniels 网站使用 Cookie 来提升您的浏览体验。